District of Delaware Makes it Harder to Corner the Market on Antibody Patents in MorphoSys v. Janssen

Zachary Silbersher

See our post in IPWatchdog. “The case is important to the growing body of patents covering biologic drugs because it delineates more precisely when functionally-claimed antibody patents can survive enablement and written description challenges.”